Making a difference to the people we help treat by creating value and improving healthcare outcomes through connecting innovative manufacturers with Australasian customers.

Luminex – Proteomics to Genomics

  • Do you have a multiplex instrument?
  • Running qPCR assays regularly?
  • Ready to detect up to 150 genetic targets from a single well?

Unlock the power of ultra-high multiplexing—streamline your workflow, save time, and get more data from every run.


  • Pathogen identification
  • Gene expression​
  • SNP typing​
  • Copy number variation analysis ​
  • miRNA analysis​

Use Luminex MagPlex TAG beads to expand your genomic multiplexing capabilities

MagPlex-TAG Microspheres are are oligonucleotide-coupled polystyrene microparticles. Each one of the color-coded beads has a unique 24 base DNA sequence called an “anti-TAG” covalently coupled to its surface. These beads enable you to quickly and easily design custom bead arrays simply by adding a complementary “TAG” sequence to the primer or probes in your assay and hybridizing those TAGs to the anti-TAG sequence on the corresponding microsphere.


Explore the Luminex xMAP Cookbook Catalogue

Download >

Download the Luminex Microspheres xMAP Catalogue brochure

Click Here >


Want to find out more about developing your genetic multiplexing assay?

Contact us >

* Refer to MagPlex TAG regions to confirm which groups you can use with your instrument.

Request a Quote

Request Quote

Recent Posts

Roche – New KAPA NGS Reagents

Roche KAPA kits offer a range of high-performance products for molecular biology applications in next-generation sequencing (NGS). KAPA RNA EvoPrep Kit The KAPA RNA EvoPrep…

Read full article

2027 Abacus dx Emerging Investigators Grant

COMING SOON Grant in Research Funding Empowering the Next Generation of Scientific Leaders Stay tuned for the 2027 Abacus dx Emerging Investigators Grant. More information…

Read full article

Developing Diagnostic Kits for Ovarian Cancer

In Australia, ovarian cancer is the deadliest reproductive cancer. The average five‑year survival rate sits at around 49%, compared with about 92% for breast cancer,…

Read full article